Skip to content

Comparative study on the effectiveness of two surgical methods for early cervical cancer

Comparative study on the effectiveness of two surgical methods for early cervical cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075118
Enrollment
Unknown
Registered
2023-08-25
Start date
2023-09-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Stage Cervical Cancer

Interventions

TARH:TARH
Laparoscopic surgery based on the open stateGasless TLRH:Laparoscopic surgery based on the open state

Sponsors

Shenyang Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cervical adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma who are at least 18 years old; 2. Patients with ECOG presentation status of 0-1 and FIGO (2018) clinical staging of IA1 disease with lymphatic vessel invasion, IA2 disease or IB1 disease (<2 cm, limited to cervix) were randomly divided into open or minimally invasive radical hysterectomy in a 1:1 ratio; 3. Patients can undergo type II or III radical hysterectomy (Piver classification) and pelvic lymph node resection. According to the Sedlis standard, postoperative adjuvant radiotherapy is recommended and widely accepted.

Exclusion criteria

Exclusion criteria: 1. Neuroendocrine, transparent or serous cell types; 2. Clinical advanced diseases with tumor size greater than 4cm (IB2-IV stage); 3. Uterine size greater than 12 centimeters, history of abdominal or pelvic radiation therapy, or evidence of metastatic disease on positron emission tomography (computed tomography, magnetic resonance imaging, or computed tomography); 4. If researchers believe that patients are unable to undergo surgery or cannot withstand the lithotomy position, they will also be excluded. Or lack compliance or reside too far away from the treatment center, making it impossible to conduct sufficient follow-up.

Design outcomes

Primary

MeasureTime frame
Disease free survival;Length of stay;

Secondary

MeasureTime frame
Recurrence rates;Postoperative pain ;The Quality of Life;Operation time;Estimated blood loss;operative complications;The levels of CD4 + T lymphocytes, NK cells and CD4 + CD25 high CD127 low Treg;Hemodynamic parameters;MAP;SV;Costs;

Countries

China

Contacts

Public ContactYansong Liu

Shenyang Women's and Children's Hospital

15040291279@163.com+86 139 4000 7179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026